ANDREEA TEODORESCU, PETRU IFTENI, PAULA PETRIC, SEBASTIAN TOMA, ADRIAN BARACAN, CLAUDIA GAVRIS, GHEORGHE G. BALAN, VLADIMIR POROCH, ALINA MIHAELA PASCU ACETYLCHOLINESTERASE INHIBITORS TEST CONFIRMED MYASTHENIA GRAVIS IN PSYCHOSIS REMITTED BY ARIPIPRAZOLE Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease affecting the neuromuscular junction and causes weakness in the skeletal muscles. The acetylcholine receptor is usually attacked in skeletal muscles, but other components of neuromuscular junction, such as muscle-specific receptor tyrosine kinase, may be affected. MG can be life-threatening when the respiratory muscles are involved. The first symptom in about 2 out of 3 cases is the damage of the extrinsic eye muscles. The condition is treatable, so an early recognition is needed. Although there have been reports of associations between psychosis and myasthenia gravis it is unclear if psychotic symptoms in MG are an integral part of the various manifestations of this disease, or are due to another co-occurring distinct disorder. Sometimes psychotic episodes could disguise the simptoms of myastenia gravis, and delay the diagnosis.